Skip to the answer

Selegiline

Selegiline is a monoamine oxidase (MAO) inhibitor used as an add-on treatment for Parkinson’s disease (oral forms) and to treat major depressive disorder (the Emsam skin patch).

Brand names EldeprylZelaparEmsamAnipryl
Drug classes Monoamine Oxidase Inhibitor
Rx Forms 4
Dr. Brian Staiger, PharmD, BCPS
Reviewed by Last reviewed Jul 10, 2026 Content updated Oct 2, 2026
🧬 Where this information comes from Click to expand

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 14 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →

✓No current FDA shortage listed · checked Oct 5, 2026
Other forms & routes:
Transdermal
Selegiline at a glance The quick version — the full detail is in the Patient Information Guide below.
Dr. Brian Staiger, PharmD, BCPS
The Pharmacist’s Take By · Clinical pharmacist · Written

Selegiline, an older drug around since 1989 and available generically, blocks monoamine oxidase (MAO), the enzyme that breaks down dopamine and serotonin; tablets, capsules and Zelapar mainly block its MAO-B form as an add-on when levodopa/carbidopa starts losing ground in Parkinson's disease, while the Emsam skin patch blocks both forms to treat major depressive disorder. Most people tolerate it fairly well, noticing headache, trouble sleeping, dry mouth or redness under the patch. Emsam's boxed warning covers suicidal thoughts in young people, and any form can trigger dangerous blood pressure spikes or serotonin overload with the wrong drugs or foods, so report mood changes or a sudden severe headache promptly.

Clinical pearls

  • Put Zelapar on the tongue each morning before breakfast, without liquid, and skip food and drink five minutes either side.
  • Ask before any cough or cold product, since pseudoephedrine, phenylephrine and dextromethorphan are classic problem ingredients with selegiline.
  • On Emsam's higher strengths, avoid tyramine-rich foods like aged cheese, cured meats, tap beer, sauerkraut and soy sauce.
  • Oral forms, especially Zelapar, can cause sudden sleep attacks and dizziness on standing, so be careful driving at first.
How we write & review this content — our editorial policy →
How you get itPrescription only
Comes asTablet, Capsule, Skin patch +1
Earliest FDA record1989
Companies listing it with the FDA13
FDA label last updatedJun 1, 2021
FDA’s strongest warning (boxed)None on the label

Patient information guide A plain-language walkthrough of Selegiline, written from its FDA label.

What Selegiline is used for

▾

Selegiline is used for different conditions depending on the product.

  • Selegiline hydrochloride tablets and capsules: add-on for Parkinson’s disease with levodopa/carbidopa when its benefit wanes.
  • Zelapar (orally disintegrating tablet): the same Parkinson’s disease use.
  • Emsam (skin patch): major depressive disorder in adults.

How Selegiline works

▾

Selegiline blocks monoamine oxidase, an enzyme that breaks down brain chemicals like dopamine, serotonin and norepinephrine. At Parkinson’s disease doses it mainly blocks the MAO-B form, which may raise dopamine. At antidepressant doses via the Emsam patch, it blocks both MAO-A and MAO-B, which is thought to boost mood-related brain chemicals.

Selegiline dosage

▾

Selegiline tablets and capsules are swallowed. Zelapar dissolves on the tongue. Emsam is a once-daily patch.

  • Zelapar: taken once daily in the morning before breakfast, without liquid, with no food or drink 5 minutes before or after.
  • Emsam: one patch every 24 hours on dry, intact skin of the upper torso, upper thigh or outer upper arm.

Follow your prescriber’s directions and the label.

Dosing details from the FDA-approved label

From the Selegiline prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.

  • Emsam (selegiline transdermal) - Initial Treatment
    • Apply to dry, intact skin on the upper torso (below the neck and above the waist), upper thigh or the outer surface of the upper arm once every 24 hours
    • Recommended starting dose and target dose is 6 mg per 24 hours
    • Based on clinical judgment, dose increases in increments of 3 mg per 24 hours at intervals of no less than 2 weeks
    • Maximum: 12 mg per 24 hours
    • Tyramine-rich foods and beverages to be avoided beginning on the first day of 9 mg per 24 hours or 12 mg per 24 hours, and for 2 weeks after a dose reduction to 6 mg per 24 hours or discontinuation of those doses
  • Emsam - Geriatric (elderly patients 65 years and older)
    • EMSAM 6 mg per 24 hours daily
  • Zelapar (selegiline orally disintegrating tablet) - General dosage
    • Initiate with 1.25 mg once a day for at least 6 weeks
    • After 6 weeks, the dose may be increased to 2.5 mg once a day if a desired benefit has not been achieved and the patient is tolerating ZELAPAR. Take in the morning before breakfast and without liquid, placing the tablet on top of the tongue
    • Maximum: 2.5 mg a day (doses greater than 2.5 mg a day should ordinarily be avoided)
    • Avoid food or liquids for 5 minutes before and after taking
  • Zelapar - Mild to moderate hepatic impairment (Child-Pugh score 5 to 9)
    • Daily dose should be reduced (from 2.5 to 1.25 mg daily), depending on the clinical response
    • Not recommended in severe hepatic impairment (Child-Pugh score greater than 9)
  • Zelapar - Mild to moderate renal impairment (CLcr 30 to 89 mL/min)
    • No dose adjustment required
    • The maintenance dose (1.25 mg or 2.5 mg) is determined by the individual clinical response
    • Not recommended in severe renal impairment and end-stage renal disease
Read the label’s full dosing text

2 DOSAGE AND ADMINISTRATION • Initiate treatment with 1.25 mg given once a day for at least 6 weeks; after 6 weeks, the dose may be escalated to 2.5 mg once a day ( 2.1 ) • Place tablet on top of the tongue where the tablet will disintegrate in seconds; avoid food and liquid intake 5 minutes before and after each dose ( 2.1 ) • In patients with mild or moderate hepatic impairment, the dose should be reduced to 1.25 mg; ZELAPAR is not recommended in patients with severe (Child-Pugh score >9) hepatic impairment ( 2.2 ) 2.1 General Dosage Recommendations Initiate treatment with 1.25 mg given once a day for at least 6 weeks. After 6 weeks, the dose may be increased to 2.5 mg given once a day if a desired benefit has not been achieved and the patient is tolerating ZELAPAR. There is no evidence that doses greater than 2.5 mg a day provide additional benefit, and they should ordinarily be avoided because of the potential increased risk of adverse events. Take ZELAPAR in the morning before breakfast and without liquid. Patients should avoid ingesting food or liquids for 5 minutes before and after taking ZELAPAR. Patients should not attempt to push ZELAPAR through the foil backing. Patients should PEEL BACK the backing of one or two blisters (as prescribed) with dry hands, and GENTLY remove the tablet(s). Patients should IMMEDIATELY place the ZELAPAR tablet(s) on top of the tongue where it will disintegrate in seconds. 2.2 Patients with Hepatic Impairment In patients with mild to moderate hepatic disease (Child-Pugh score 5 to 9), the daily dose of ZELAPAR should be reduced (from 2.5 to 1.25 mg daily), depending on the clinical response. ZELAPAR is not recommended in patients with severe hepatic impairment (Child-Pugh score greater than 9) [see Use in Specific Populations ( 8.6 ) and Clinical Pharmacology (12.3) ] . 2.3 Patients with Renal Impairment No dose adjustment of ZELAPAR is required in patients with mild to moderate renal impairment (creatinine clearance [CLcr] 30 to 89 mL/min). The maintenance dose of ZELAPAR (1.25 mg or 2.5 mg) is determined by the individual clinical response. ZELAPAR is not recommended in patients with severe renal impairment and patients with end-stage renal disease [ESRD] (creatinine clearance [CLcr] <30 mL/min) [see Use in Specific Populations ( 8.7 ) and Clinical Pharmacology (12.3) ] .

Read the full Dosage and Administration section on DailyMed →

Selegiline side effects

▾

Common side effects, mostly reported with Emsam, include:

Common side effects

  • Application site reaction (Emsam patch), such as skin redness
  • Headache
  • Trouble sleeping (insomnia)
  • Diarrhea
  • Dry mouth
  • Indigestion
  • Rash
  • Sore throat or sinus infection
  • Application site reaction

When to get medical help

  • Thoughts of suicide, new or worsening depression, or unusual changes in mood or behavior, especially early in treatment or after a dose change
  • Sudden, severe headache or very high blood pressure (hypertensive crisis), particularly after high-tyramine foods or interacting drugs
  • Signs of serotonin syndrome: confusion, agitation, hallucinations, sweating, fever, shivering, muscle rigidity or twitching, fast heartbeat
  • Falling asleep suddenly during daily activities, such as driving (Zelapar)
  • Hallucinations, paranoia, confusion or other psychotic-like behavior
  • Intense new urges, such as gambling, spending, binge eating or sexual urges
  • Fainting or dizziness when standing up
  • New or worse uncontrolled movements (dyskinesia)

Seek help for suicidal thoughts, severe headache or blood pressure spikes, signs of serotonin syndrome, hallucinations, sudden sleep episodes or intense new urges.

Selegiline warnings and precautions

▾
  • Emsam has a boxed warning for suicidal thoughts and behaviors, especially in young people.
  • Emsam is contraindicated under age 12 because of hypertensive crisis risk.
  • Do not exceed recommended doses; selegiline loses its selectivity and blood pressure risks rise.
  • Serotonin syndrome can occur with antidepressants and other serotonergic drugs and can be fatal.
  • Zelapar can cause sudden sleep episodes, low blood pressure on standing, worse dyskinesia, hallucinations, compulsive urges and mouth irritation.

Selegiline interactions

▾

Selegiline interacts with many drugs and some foods.

  • SSRIs, SNRIs, tricyclic antidepressants: serotonin syndrome risk.
  • Meperidine, tramadol, methadone, pentazocine, propoxyphene, dextromethorphan: contraindicated with Emsam for serotonin syndrome risk.
  • Carbamazepine: contraindicated with Emsam, possible hypertensive crisis.
  • Pseudoephedrine, phenylephrine, ephedrine, amphetamines, buspirone: may substantially raise blood pressure.
  • Tyramine-rich foods (aged cheese, cured meats, tap beer, soy sauce): hypertensive crisis risk; avoidance is required with higher Emsam doses.
  • Alcohol: not recommended with Emsam.

Interactions listed in the FDA-approved label

From the Selegiline prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

  • Serotonergic drugs: Serious, sometimes fatal, CNS toxicity referred to as serotonin syndrome has been reported with the combination of nonselective MAOIs and serotonergic drugs. Use of EMSAM with these drugs is contraindicated.
  • Tyramine-rich foods and beverages: EMSAM can inhibit intestinal MAO, so large amounts of tyramine may enter the systemic circulation and precipitate a sudden, large rise in blood pressure or hypertensive crisis. Data for 6 mg per 24 hours support that a modified diet is not required at this dose; patients on 9 mg or 12 mg per 24 hours should avoid the Table 5 foods and beverages from the first day and for 2 weeks after dose reduction to 6 mg or discontinuation.
  • Sympathomimetic amines and buspirone (amphetamines, pseudoephedrine, phenylephrine, phenylpropanolamine, ephedrine, cold or weight-reducing products): Use with EMSAM may produce substantial elevations in blood pressure. Monitor blood pressure.
  • Carbamazepine: Carbamazepine is contraindicated with MAOIs, including selegiline. Do not use together (contraindicated).
  • Alcohol: EMSAM has not been shown to increase the impairment of mental and motor skills caused by alcohol (0.75 mg per kg); no clinically meaningful change in selegiline exposure was seen. Use of alcohol while taking EMSAM is not recommended; no EMSAM dose adjustment needed.
  • Alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole): No clinically meaningful change in selegiline exposure was seen when co-administered. No dose adjustment for EMSAM is needed.
  • Alprazolam, ibuprofen, levothyroxine, olanzapine, risperidone, warfarin, strong CYP3A4 inhibitors (e.g., ketoconazole) (effect of EMSAM on these drugs): EMSAM had no clinically relevant effect on the pharmacokinetics of these drugs. No dose adjustment of these drugs is necessary.
Read the label’s full interactions text

7 DRUG INTERACTIONS 7.1 Opioid Drugs Because serious, sometimes fatal reactions have been precipitated with concomitant use of opioid drugs (e.g., meperidine and its derivatives, methadone, or tramadol) and MAOIs, including selective MAO-B inhibitors, concomitant use of these drugs with ZELAPAR is contraindicated [see Contraindications ( 4 ) and Warnings and Precautions ( 5.2 )] . At least 14 days should elapse between discontinuation of ZELAPAR and initiation of treatment with these drugs. 7.2 Dextromethorphan The combination of MAO inhibitors and dextromethorphan has been reported to cause brief episodes of psychosis or bizarre behavior. Therefore, in view of ZELAPAR’s MAO inhibitory activity, dextromethorphan should not be used concomitantly with ZELAPAR [see Contraindications (4) ] . 7.3 MAO Inhibitors ZELAPAR is contraindicated for concomitant use with other drugs in the MAOI class or other drugs that are potent inhibitors of monoamine oxidase (including linezolid, an oxazolidinone antibacterial, which also has reversible nonselective MAO inhibition activity) because of the increased risk for hypertensive crisis [see Contraindications (4) and Warnings and Precautions (5.1 )] . At least 14 days should elapse between discontinuation of ZELAPAR and initiation of treatment with other MAOIs. 7.4 Sympathomimetic Medications Uncontrolled hypertension, including hypertensive crisis, has been reported when taking the recommended dose of swallowed selegiline and a sympathomimetic medication (ephedrine). 7.5 Tyramine/Selegiline Interaction The enzyme, monoamine oxidase (MAO) (primarily type A), in the gastrointestinal tract and liver provides protection from ingested amines (e.g., tyramine) that, if absorbed, have the capacity to cause uncontrolled hypertension (tyramine reaction).

Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

🌿102 supplements and herbs with documented Selegiline interactions, ranked by severity Check Selegiline against a supplement or herb →

Before taking Selegiline

▾
  • Emsam: not for children under 12; not recommended ages 12 to 17.
  • Emsam: not for people with pheochromocytoma.
  • Emsam: may cause fetal harm; breastfeeding not recommended during treatment and for 5 days after the last dose.
  • Older adults: recommended Emsam dose is 6 mg per 24 hours; Zelapar has higher sleepiness and low blood pressure risk.
  • Zelapar: contains phenylalanine (PKU concern); lower dose in mild to moderate liver disease; not recommended in severe liver or kidney disease.
  • Zelapar: people with a major psychotic disorder should ordinarily not use it.

Selegiline overdose

▾

No specific overdose experience is documented, but overdoses are likely to block both MAO types, resembling overdoses of other MAO inhibitors. Symptoms can be delayed up to 12 hours and may include agitation, severe headache, hallucinations, seizures, and blood pressure or heart rhythm changes. Get emergency help or call Poison Control right away.

What Selegiline does in the body

▾

Selegiline blocks MAO-B more strongly than MAO-A, but that selectivity is lost as the dose rises. At Emsam antidepressant doses, it blocks both. Blocking MAO in the gut can let tyramine from food enter the body and raise blood pressure sharply.

How your body processes Selegiline

▾

With the Emsam patch, about 25% to 30% of the drug on average is absorbed over 24 hours, bypassing heavy first-pass metabolism in the liver. Selegiline spreads quickly to body tissues and the brain. It is broken down by several liver enzymes, and its metabolites are cleared mainly in urine. Half-lives of selegiline and its metabolites range from 18 to 25 hours.

How to store Selegiline

▾

stored inside a clear child-resistant outer pouch and is packaged in a carton. Store at controlled room temperature, 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Store blister tablets in sachet pouch at all times.

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

102

Supplements & herbs that interact with Selegiline

102 supplements and herbal products have documented interactions with Selegiline in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.

Severity mix
  • Major · 14
  • Moderate · 75
  • Minor · 13
ACTIVATED CHARCOAL Major BEER Major BITTER ORANGE Major BREWER'S YEAST Major COWHAGE Major FEVER BARK Major LITHIUM Major RAUVOLFIA VOMITORIA Major +94 more
Every supplement checked against Selegiline — ranked by severity The full interaction hub: 14 major · 75 moderate · 13 minor · every one linked to its full report. Check Selegiline against your exact supplements

Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.

1

Nutrient depletion considerations

Selegiline has been associated with lower levels of 1 nutrient in the clinical literature. This does not mean a deficiency will occur — it means these may be worth discussing with your pharmacist or healthcare provider, especially with long-term use.

SODIUM Moderate Depletion
See the full Selegiline nutrient depletion report

Educational information from a licensed clinical database (Natural Medicines) — not medical advice. Do not start or stop medications or supplements without professional guidance.

Selegiline: pharmacist answers to common questions

Quick, plain-English answers to the questions patients ask most about Selegiline — the kind of thing our pharmacy team would talk through with you at the counter.

What is selegiline for?

▾
It depends on the product. The tablets, capsules and Zelapar are add-ons for Parkinson’s disease in people on levodopa/carbidopa whose response has worsened. The Emsam patch treats major depressive disorder in adults.

How do I take Zelapar?

▾
Take it in the morning before breakfast. With dry hands, peel back the foil, then place the tablet on your tongue, where it dissolves in seconds. Skip food and drink for 5 minutes before and after.

Do I need to change my diet?

▾
With the Emsam patch at the 9 or 12 mg per 24 hours doses, you must avoid tyramine-rich foods such as aged cheese, cured meats and tap beer. Keep this up for 2 weeks after lowering or stopping. Ask your pharmacist or prescriber about your dose.

Can I take cold medicine or other antidepressants with it?

▾
Check with me first. Many antidepressants, some pain medicines, dextromethorphan and carbamazepine can be dangerous with selegiline. Decongestants like pseudoephedrine can raise your blood pressure.

What side effects should I call about?

▾
Call right away for suicidal thoughts, severe headache, signs of serotonin syndrome, hallucinations, or suddenly falling asleep during daily activities. Mild skin redness at the patch site, headache and dry mouth are more common.

Is it safe in pregnancy?

▾
Emsam may cause fetal harm, and breastfeeding is not recommended during treatment and for 5 days after the last dose. Talk with your doctor about the risks and benefits of treating depression.

Is Selegiline available over the counter?

▾
No. Selegiline is a prescription medicine: every Selegiline product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

When was Selegiline first available?

▾
The earliest FDA record we hold for Selegiline is from 1989: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when Selegiline was first used.

Who makes Selegiline?

▾
13 companies currently list Selegiline products in the FDA's NDC Directory, including Viatris Specialty LLC, Apotex Corp., Bryant Ranch Prepack. That count includes repackagers and distributors as well as manufacturers (companies that sell only the raw ingredient are not counted), so fewer companies actually make it; the label on your bottle names the one that supplied yours.

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

More about Selegiline on HelloPharmacist

📊Selegiline supplement interactions102 checked — ranked by severity 🌿Drug & Supplement CheckerSelegiline vs. vitamins & herbs 💬Ask a PharmacistFree answer, usually < 24h 🔎NDC & pricing lookupFind Selegiline NDCs & costs 🅰️Browse Drugs A–ZLook up any medication
Detailed data & references for Selegiline Forms & strengths, pricing, billing codes, manufacturers, safety reports and sourcing — the data behind the page. Most people can stop here. Each section below opens on a tap.

Selegiline forms and strengths (how it comes)

Selegiline is available in 4 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Tablet

By mouth
How this form is used
What it may be used for
  • Selegiline hydrochloride tablets are an add-on for Parkinson’s disease in people on levodopa/carbidopa whose response has worsened.
Available strengths 1 strength
5 mg
14 FDA-listed product records ⓘ

Capsule

By mouth
How this form is used
What it may be used for
  • Selegiline hydrochloride capsules are an add-on for Parkinson’s disease in people on levodopa/carbidopa whose response has worsened.
Available strengths 1 strength
5 mg
13 FDA-listed product records ⓘ

Skin patch

Through the skin
Brands Emsam
How this form is used
What it may be used for
  • Emsam treats major depressive disorder in adults.
Important instructions
  • Apply Emsam to dry, intact skin on the upper torso, upper thigh or outer upper arm.
  • Emsam is applied once every 24 hours.
  • Full antidepressant effect with Emsam may be delayed.
  • Emsam at higher doses requires avoiding tyramine-rich foods and drinks.
Available strengths 6 strengths
6 mg/24h SELEGILINE 6 mg/24h 9 mg/24h SELEGILINE 9 mg/24h 12 mg/24h SELEGILINE 12 mg/24h
6 FDA-listed product records ⓘ

Orally disintegrating tablet

By mouth
Brands Zelapar
How this form is used
What it may be used for
  • Zelapar is an add-on for Parkinson’s disease in people on levodopa/carbidopa whose response has worsened.
Important instructions
  • Zelapar is placed on top of the tongue, where it dissolves in seconds.
  • Take Zelapar in the morning before breakfast, without liquid.
  • Avoid food and liquid for 5 minutes before and after Zelapar.
  • With Zelapar, peel back the foil with dry hands; do not push the tablet through the foil.
Available strengths 1 strength
1.25 mg
3 FDA-listed product records ⓘ

Selegiline on the U.S. market: products, makers and brands

How Selegiline appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

13 companies list 17 Selegiline product records with the FDA, mostly as tablet, capsule, skin patch; the earliest marketing or approval year on record is 1989. Brand names on the directory include Eldepryl, Zelapar, Emsam and 1 more; the rest are generics.

4
Dose forms ⓘ
13
Labelers (makers, repackagers, distributors)
3
Brand names
17
FDA-listed product records ⓘ
1989
Earliest FDA record ⓘ

FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

Also listed with the FDA, not a patient dose form: Powder (12) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.

Viatris Specialty LLC18%
Apotex Corp.12%
Bryant Ranch Prepack12%
A-S Medication Solutions6%
A2A Integrated Pharmaceuticals6%
Bausch Health US, LLC6%
Other makers41%

Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

How widely Selegiline is used (Medicaid data)

A general measure of how commonly Selegiline is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.

Think of this as a proxy for how widely Selegiline is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.

2,305
Medicaid prescriptions filled (Q1–Q4 2025)
$2.4M gross Medicaid reimbursement (before mandatory rebates — net cost is lower)

How commonly is Selegiline prescribed? Of the 1,601 medications we measure, Selegiline ranks #1,176 by Medicaid prescriptions — more than 27% of them.

Where Selegiline ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5
Total prescriptions — #1,176 of 1,601
#1,171 Naphazoline / Pheniram... 2,382 Rx #1,172 Trilaciclib Injection 2,352 Rx #1,173 Avatrombopag 2,342 Rx #1,174 Setmelanotide Injectio... 2,332 Rx #1,175 Pomalidomide 2,329 Rx #1,176 Selegiline 2,305 Rx #1,177 Levobunolol Ophthalmic 2,275 Rx #1,178 Voclosporin 2,236 Rx #1,179 Ganciclovir 2,228 Rx #1,180 Omadacycline 2,212 Rx #1,181 Omadacycline Injection 2,212 Rx

Utilization by Selegiline product

Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.

The 5 mg oral tablet is the most-dispensed Selegiline product — about 40% of these Medicaid prescriptions.

selegiline hydrochloride 5 MG Oral Tablet Most dispensed

930 Medicaid prescriptions (Q1–Q4 2025) 40% of Selegiline prescriptions shown $66,037 gross reimbursement (before rebates) ≈ $71 per prescription (gross)

Summed across the 2 of 15 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 859193

24 HR selegiline 0.25 MG/HR Transdermal System

507 Medicaid prescriptions (Q1–Q4 2025) 22% of Selegiline prescriptions shown $1.2M gross reimbursement (before rebates) ≈ $2,302 per prescription (gross)

Summed across the 1 of 4 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 865206

selegiline hydrochloride 5 MG Oral Capsule

391 Medicaid prescriptions (Q1–Q4 2025) 17% of Selegiline prescriptions shown $23,910 gross reimbursement (before rebates) ≈ $61 per prescription (gross)

Summed across the 3 of 17 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 859186

24 HR selegiline 0.5 MG/HR Transdermal System

265 Medicaid prescriptions (Q1–Q4 2025) 11% of Selegiline prescriptions shown $620,677 gross reimbursement (before rebates) ≈ $2,342 per prescription (gross)

Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 865214

24 HR selegiline 0.375 MG/HR Transdermal System

212 Medicaid prescriptions (Q1–Q4 2025) 9% of Selegiline prescriptions shown $477,664 gross reimbursement (before rebates) ≈ $2,253 per prescription (gross)

Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 865210

Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.

Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Selegiline, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 8 of 40 listed Selegiline NDCs with Medicaid activity.

Compare Selegiline products

A representative set of FDA-listed product records for Selegiline — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Showing 17 of 17 products — FDA National Drug Code Directory. See every product, package size and price: browse all 17 Selegiline NDCs →

Selegiline recall history

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list no Selegiline recalls since July 2021.

✅No Selegiline recalls on record since July 2021

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.

RxNorm Concept Web — From Ingredient to Every Form and Strength

This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.

Ingredient (IN) Selegiline RxCUI 9639 5 dose forms · 11 strengths
  1. Dose form (SCDF) Disintegrating Oral Tablet RxCUI 643052 In current FDA listings
    Clinical drug / strength (SCD) hydrochloride 1.25 MG RxCUI 859190
  2. Dose form (SCDF) Oral Capsule RxCUI 374522 In current FDA listings
    Clinical drug / strength (SCD) hydrochloride 5 MG RxCUI 859186
  3. Dose form (SCDF) Oral Solution RxCUI 373841 No current FDA listing
    Clinical drug / strength (SCD) hydrochloride 2 MG/ML RxCUI 865222
  4. Dose form (SCDF) Oral Tablet RxCUI 373842 In current FDA listings
    Clinical drug / strength (SCD) hydrochloride 1.25 MG RxCUI 865218 hydrochloride 10 MG RxCUI 865220 hydrochloride 15 MG RxCUI 880383 hydrochloride 30 MG RxCUI 897069 hydrochloride 5 MG RxCUI 859193

Look up RxCUI 9639 in the RxCUI Atlas →

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

💵 What Selegiline costs pharmacies (NADAC benchmark)

The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.

FormStrengthPharmacy acquisition benchmark
Patch · Transdermal 6 mg/24h $75.00 each NDC details & price history
Patch · Transdermal SELEGILINE 6 mg/24h $75.00 each NDC details & price history
Patch · Transdermal 9 mg/24h $75.18 each NDC details & price history
Patch · Transdermal SELEGILINE 9 mg/24h $75.18 each NDC details & price history
Patch · Transdermal 12 mg/24h $75.40 each NDC details & price history
Patch · Transdermal SELEGILINE 12 mg/24h $75.40 each NDC details & price history
Why show this? Your out-of-pocket cost depends on insurance, pharmacy markup, and discounts — but the acquisition benchmark tells you whether the medication itself is inexpensive or costly, which strengths cost more per dose, and whether a cash-price quote is in a reasonable range. Each row links to the NDC-level record with its full price history.

Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.

Selegiline brand names

Selegiline is sold under 4 brand names in the FDA directory — Eldepryl, Zelapar, Emsam, Anipryl. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.

Eldepryl Zelapar Emsam Anipryl

Who makes Selegiline: manufacturers and labelers

13 companies list Selegiline products with the FDA. By number of product records, the largest are Viatris Specialty LLC, Apotex Corp., Bryant Ranch Prepack. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

Viatris Specialty LLC 3 Apotex Corp. 2 Bryant Ranch Prepack 2 A-S Medication Solutions 1 A2A Integrated Pharmaceuticals 1 Bausch Health US, LLC 1 Chartwell RX, LLC 1 Golden State Medical Supply, Inc. 1 Marlex Pharmaceuticals, Inc. 1 Novitium Pharma LLC 1 Proficient Rx LP 1 Rising Pharma Holdings, Inc. 1 i3 Pharmaceuticals, LLC 1

Selegiline drug class (RxNorm)

Selegiline belongs to the Monoamine Oxidase Inhibitor class.

Pharmacologic class Monoamine Oxidase Inhibitor, Monoamine Oxidase Type B Inhibitor
Drug family (ATC) Monoamine oxidase B inhibitors
How it works Monoamine Oxidase Inhibitors, Monoamine Oxidase-B Inhibitors

Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.

Sources for this Selegiline page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. ✓ Linked label effective Jun 1, 2021
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Selegiline.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.
🧾 Clinical label set — FDA-filed SPL labels retained for Selegiline after exact ingredient or ingredient-combination matching and applicable route/form matching
Clinical labels in scope
14
Finished products in the current FDA directory
17
Companies listing them (makers, repackagers, distributors)
13
FDA labeler codes behind them ⓘ
13
Linked representative label ⓘ
Bausch Health US, LLC
Linked label effective
Jun 1, 2021
Composite sections available
23
Linked SPL Set ID
380d7717-2a79-42f3-a712-efe5e7696ba0
Linked SPL Document ID
ff911cbd-70ba-4034-8831-a81676d7811c
Open the linked representative label on DailyMed ↗

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Bausch Health US, LLC is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →